TICKERNERD
Menu
GILDGILDHealthcare · Drug Manufacturers - General

GILD Stock Forecast: Gilead Sciences, Inc. Price Predictions for 2026-2027

Last close, 14 Aug 2026
$138
+0.16% on the day

The 29 Wall Street analysts covering Gilead Sciences, Inc. hold a median 12-month price target of $160 — +15.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 91 of 100 as at 15 Aug 2026 — among the strongest tenth. Here, the model and the Street point the same way.

Market cap
$171.6B
Ticker Nerd rank
91 / 100
Median analyst target
$160
Analysts covering
29
Total return, dividends reinvested
1W
+3.9%
1M
+6.4%
YTD
+14.0%
1Y
+19.1%
From 52W high
−10.2%
From 52W low
+27.4%
$109
$154
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

GILD stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Gilead Sciences, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 15 Aug 2026
91 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Volatility
100
Value
99
Accruals
98
Quality
96
Revisions
69
Momentum
64
Growth
52
Issuance
50
Size
2

Volatility (100): The share price has been relatively steady.

Issuance (50): The company has been issuing shares or taking on financing, diluting existing holders.

Size (2): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

GILD stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on GILD, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$100$120$140$160$180Oct 25Jan 26Apr 26Jul 26GILDHigh $180Median $160Low $123

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says29 analysts
22 Buy7 Hold0 Sell
Low $123Median $160High $180

The green dot is the last close — the median target sits +15.6% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 2 moved their price target up and 6 moved it down.

DateFirmActionRatingTarget
5 Aug 2026Cantor FitzgeraldReiteratesOverweight$155
5 Aug 2026NeedhamReiteratesBuy$170
5 Aug 2026RBC CapitalMaintainsSector Perform$120 → $123
29 July 2026BarclaysMaintainsEqual-Weight$155 → $145
27 July 2026Morgan StanleyMaintainsOverweight—
27 July 2026Morgan StanleyMaintainsOverweight$166 → $165
21 July 2026Leerink PartnersDowngradeMarket Perform—
21 July 2026Leerink PartnersDowngradeMarket Perform$146 → $127
8 July 2026Morgan StanleyMaintainsOverweight—
8 July 2026Morgan StanleyMaintainsOverweight$168 → $166
7 July 2026RBC CapitalMaintainsSector Perform—
7 July 2026RBC CapitalMaintainsSector Perform$122 → $120
7 July 2026Truist SecuritiesMaintainsBuy$157 → $156
7 July 2026Truist SecuritiesMaintainsBuy—
6 July 2026Cantor FitzgeraldReiteratesOverweight$155
6 July 2026Cantor FitzgeraldReiteratesOverweight—
6 July 2026HSBCUpgradeBuy$133 → $155
6 July 2026HSBCUpgradeBuy—
16 June 2026Cantor FitzgeraldReiteratesOverweight—
20 May 2026Maxim GroupUpgradeBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. GILD appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

GILD analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
8
Analysts cutting
4
Fundamentals

Gilead Sciences, Inc. (GILD) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
17.9×

Cheaper than 43% of US stocks

Price / sales
5.6×

Cheaper than 23% of US stocks

Price / book
14.5×

Cheaper than 7% of US stocks

EV / EBITDA
13.2×

Cheaper than 29% of US stocks

Growth & margins
Revenue growth (YoY)
10.2%

Higher than 53% of US stocks

Earnings growth (YoY)
10.2%

Higher than 48% of US stocks

Gross margin
79.8%

Higher than 90% of US stocks

Operating margin
33.7%

Higher than 89% of US stocks

Net margin
−10.6%

Higher than 20% of US stocks

Returns & dividend
Return on equity
−20.7%

Higher than 31% of US stocks

Return on assets
14.1%

Higher than 96% of US stocks

Dividend yield
2.4%

Higher than 54% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

GILD vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - General
CompanyMarket capTKN rank
GILDGilead Sciences, Inc.$171.6B
91
PFEPfizer Inc.$152.3B
78
AMGNAmgen, Inc.$223.8B
91
BMYBristol Myers Squibb Co.$129.9B
99
MRKMerck & Co., Inc.$337.2B
81
ABBVAbbVie, Inc.$440.7B
94
JNJJohnson & Johnson$627.0B
92

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Gilead Sciences, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest GILD news & analysis

Assembly Biosciences: Gilead Advancements For GS-1179 And ABI-6250 Is A Bullish Signal

Seeking Alpha · 16 Aug 2026positive

Assembly Biosciences was maintained at a 'Buy' rating, citing pipeline advancement and a strong cash position ahead of phase 2 readouts for GS-1179 (genital herpes) and ABI-6250 (chronic HDV, PBC, and PSC) expected in 2027–2028. The report highlights Assembly's partnership with Gilead on GS-1179, which provides options between milestone/royalty payments or a 40% cost-profit share.

Why it matters — A GILD watcher would care because the report underscores progress in Gilead-partnered programs GS-1179 and ABI-6250, potentially validating the value of Gilead's pipeline collaborations.

Court rules companies can't import Gilead medications from overseas in blow to AFP health programs

CNBC · 14 Aug 2026positive

A U.S. Court of Appeals upheld a preliminary injunction against several AFPs and related businesses, ruling that companies cannot import Gilead medications from overseas. The decision could pave the way for the alternative funding programs industry to shrink.

Why it matters — The ruling could reduce the flow of imported Gilead medications through alternative funding programs, potentially affecting Gilead's product distribution and pricing dynamics.

Gilead Sciences: The Market May Be Underestimating Its Growth (Rating Upgrade)

Seeking Alpha · 10 Aug 2026positive

Gilead's R&D pipeline gained momentum in the first half of 2026, with Biktarvy sales rising 6.9% year-over-year and 12.2% sequentially to about $3.77 billion in the second quarter. Livdelzi revenue grew 114.1% year-over-year to $167 million.

Why it matters — Strong second-quarter sales growth across Gilead's HIV franchise and emerging Livdelzi product point to expanding commercial and pipeline momentum that GILD watchers would track.

GILD Q2 Earnings Call Raises Outlook on HIV and PrEP Strength

Zacks Investment Research · 7 Aug 2026positive

Gilead raised its 2026 base-business outlook during its Q2 earnings call, citing strengthening momentum in HIV and PrEP, and highlighted Trodelvy growth and two potential product launches in the second half of the year.

Why it matters — A GILD watcher would care because the raised outlook and momentum in HIV/PrEP suggest the company's core business is performing better than previously expected.

Gilead Sciences: A Strong Quarter Hidden Behind Ugly Earnings

Seeking Alpha · 6 Aug 2026positive

Gilead Sciences reported strong Q2/26 revenue growth and raised guidance, driven by its HIV portfolio of Biktarvy and Descovy. Despite operating losses from recent acquisitions, free cash flow rose to $3.4 billion and debt remains manageable.

Why it matters — GILD watchers would note the robust operational performance and cash generation, though revenue concentration around HIV drugs creates a patent cliff risk in the mid-2030s.

FAQ

Frequently asked questions about GILD stock

What is the GILD stock price forecast for 2026-2027?

The 29 Wall Street analysts covering Gilead Sciences, Inc. have a median 12-month price target of $160, with estimates ranging from $123 to $180. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is GILD stock a buy right now?

Of the 29 analysts covering Gilead Sciences, Inc., 22 rate it a Buy, 7 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Gilead Sciences, Inc. 91 out of 100 across roughly 4,600 US stocks as at 15 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank GILD?

As at 15 Aug 2026, Gilead Sciences, Inc. ranks 91 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (100 of 100).

Will GILD stock go up?

No one can know that. What the data says: the median 12-month target from 29 analysts implies +15.6% from the last close, and Ticker Nerd's factor model ranks Gilead Sciences, Inc. 91 out of 100 as at 15 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the GILD stock forecast for 2030?

No analyst covering Gilead Sciences, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for GILD are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $123 to $180 over the next 12 months.

How has GILD stock performed over the past year?

Gilead Sciences, Inc. returned +19.1% over the 12 months to 14 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Gilead Sciences, Inc. do?

Gilead Sciences Inc. is a global biopharmaceutical company focused on discovering, developing, and commercializing innovative medicines for serious and life-threatening diseases.

What is the latest news on GILD?

The most recent item we track (Seeking Alpha, 16 Aug 2026): "Assembly Biosciences: Gilead Advancements For GS-1179 And ABI-6250 Is A Bullish Signal". Assembly Biosciences was maintained at a 'Buy' rating, citing pipeline advancement and a strong cash position ahead of phase 2 readouts for GS-1179 (genital herpes) and ABI-6250 (chronic HDV, PBC, and PSC) expected in 2027–2028. The report highlights Assembly's partnership with Gilead on GS-1179, which provides options between milestone/royalty payments or a 40% cost-profit share.

Company

About Gilead Sciences, Inc.

Gilead Sciences Inc. is a global biopharmaceutical company focused on discovering, developing, and commercializing innovative medicines for serious and life-threatening diseases. The company’s core franchise centers on therapies for HIV and viral hepatitis, including hepatitis B and C, where its antiviral portfolio remains widely used in clinical practice. Beyond infectious diseases, Gilead Sciences has expanded meaningfully into oncology, offering cell therapies such as CAR-T treatments for certain blood cancers and antibody-drug conjugates used in breast and bladder cancer care. It also maintains programs in liver diseases, inflammatory conditions, and respiratory disorders, aiming to address areas of high unmet medical need. Headquartered in Foster City, California, and founded in 1987, Gilead Sciences plays a significant role in the healthcare sector by supplying advanced therapeutics to hospitals, clinics, and healthcare systems worldwide, often in collaboration with research institutions and commercial partners.

CEO Mr. Daniel Patrick O'Day · 17,000 employees · United States · https://www.gilead.com